Management

Management

  • Timothy P. Noyes

    President and Chief Executive Officer
    Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
    • Steven K. Burke, M.D.

      Senior Vice President and Chief Medical Officer
      Steven Burke, M.D., joined Proteon in 2006 as our Senior Vice President and Chief Medical Officer. Prior to joining Proteon, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research at Genzyme Corporation, where he worked from 2000 to 2006. From 1994 to 2000, Dr. Burke held roles at GelTex Pharmaceuticals, including Vice President of Clinical Research and Medical Director, and before that he held positions at Glaxo. Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical College. He completed a medical residency and fellowship at Brigham and Women’s Hospital and is certified by the American Board of Internal Medicine.
      • George A. Eldridge

        Senior Vice President and Chief Financial Officer
        George Eldridge joined Proteon in 2013 as our Chief Financial Officer. Prior to joining Proteon, from 2009 to 2013, Mr. Eldridge served as a consultant to companies in the biotechnology industry, acting as a chief financial officer and providing advisory services. From 2006 to 2009, Mr. Eldridge was Chief Financial Officer of Targanta Therapeutics Corporation until its acquisition by The Medicines Company. Before working at Targanta, Mr. Eldridge served as Chief Financial Officer of Therion Biologics from 2002 to 2006, and prior to that he served as Chief Financial Officer of Curis (previously Ontogeny) and Boston Life Sciences. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.
        • Daniel P. Gottlieb

          Vice President, Corporate Development
          Daniel Gottlieb joined Proteon in 2007 and has served as our Vice President, Marketing and Business Development since 2013, prior to which he was the Senior Director of Marketing and Business Development from 2010 until 2013 and Director of Marketing and Business Development from 2007 until 2010. Prior to joining Proteon, Mr. Gottlieb served as Strategic Marketing Manager of Endovascular Products at Abbott Vascular from 2006 to 2007. Prior to that, Mr. Gottlieb spent seven years, from 1999 to 2006, at Guidant Corporation in a variety of roles, including marketing and market research, strategic planning, and business development and corporate venture investing as part of Guidant’s Compass Group. Mr. Gottlieb holds a B.A. from the University of Pennsylvania and an M.B.A. from the Tuck School of Business at Dartmouth College.
          • Scott Toner

            Senior Vice President, Commercial
            Scott Toner joined Proteon in 2015 as our Senior Vice President, Marketing. Prior to joining Proteon, from 2014 to 2015, Mr. Toner served as the VP Marketing and Sales of OPKO Health’s Renal Division. From 2013 to 2014, he served as a consultant to companies in the biotechnology industry and from 2011 to 2012 served as Senior Director, Marketing of Reata Pharmaceuticals. Prior to that, from 2007 to 2010, Mr. Toner served as Executive Director of Marketing with AMAG Pharmaceuticals. From 1985 to 2007, Mr. Toner held various roles within the domestic and international divisions of Abbott Laboratories, concentrating primarily on the nephrology and critical care therapeutic spaces. Mr. Toner holds a B.A. from Ithaca College and an M.B.A. from Drexel University.
            • Pamela Gustafson

              Vice President, Clinical Research
              Pamela Gustafson joined Proteon in 2006 and has served as our Vice President, Clinical Research since 2015, prior to which she was the Senior Director of Clinical Research from 2012 until 2014 and Director of Clinical Research from 2006 until 2012. Prior to joining Proteon, Ms. Gustafson served as Director of Clinical Operations at Trine Pharmaceuticals from 2002 to 2006. Prior to that, Ms. Gustafson worked as a Project Manager at AAI International from 1999 until 2002, LeukoSite, Inc. from 1998 until 1999, and PAREXEL International from 1996 until 1998. Prior to PAREXEL, Ms. Gustafson spent ten years, from 1986 to 1996, in drug development positions at Alkermes, Seragen, Genzyme Corporation, and the Massachusetts Eye and Ear Infirmary. Ms. Gustafson holds a B.A. from Wheaton College and an M.P.H. from Boston University. Ms. Gustafson is also certified as a Project Management Professional.
              • Matthew Kowalsky

                Vice President, Legal
                Matthew Kowalsky joined Proteon in 2016 as Vice President, Legal. Prior to joining Proteon, he served as Senior Corporate Counsel at Sanofi Genzyme from May 2015 to May 2016, supporting business development activities and marketed products for rare diseases. Mr. Kowalsky held the position of Associate General Counsel at Cubist Pharmaceuticals, Inc. from 2013 to 2015. He served as Assistant General Counsel at ARIAD Pharmaceuticals, Inc. in 2013 and Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.) from 2009 to 2013. Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.
                • John Najim

                  Vice President, Manufacturing and Process Development
                  John Najim joined Proteon in 2009 and has served as our Vice President, Manufacturing and Process Development since 2015, prior to which he was the Senior Director of Manufacturing and Process Development from 2011 until 2014 and Director of Manufacturing from 2009 until 2011. Prior to joining Proteon, Mr. Najim served as Associate Director of Manufacturing at Dyax Corporation from 2004 to 2009. Prior to that, Mr. Najim spent six years, from 1998 to 2004, in a variety of roles at Johnson and Matthey, Genzyme Transgenics and Northeastern University, including manufacturing, process development, and research development. Mr. Najim holds a B.S. in Biochemistry from Merrimack College and an M.B.A. from the Graduate School of Business at Bentley University.
                  • Marco Wong, M.D., Ph.D.

                    Medical Director
                    Marco Wong, M.D., Ph.D., joined Proteon in 2006 and has served as our Medical Director since 2011, prior to which he was Associate Director of Research and Development from 2009 until 2011 and Physician Scientist/Senior Scientist from 2006 until 2009. Prior to joining Proteon, Dr. Wong served as a Post-doctoral Research Associate at the Stowers Institute for Medical Research from 2003 to 2006, where he conducted genetic and molecular analysis of stem cells and germ cell development. He holds a B.S. from California State University and an M.D. and Ph.D. from Wayne State University School of Medicine.